Project Details
Description
Phase 2 Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
| Status | Finished |
|---|---|
| Effective start/end date | 8/1/16 → 7/31/22 |
Funding
- SEAGEN INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.